Original Sky Meter Intranet
Highlights
On April 24, the Sixth People's Hospital of Deyang City announced that it plans to introduce 25 national drugs and new drugs in short supply that have passed the comprehensive selection and evaluation of experts, of which exclusive varieties (including exclusive dosage forms, the same below) account for more than 50%;
Source: Official website of Deyang Sixth People's Hospital
According to the statistics of treatment categories, the drugs to be introduced by the Sixth People's Hospital of Deyang City are mainly blood and hematopoietic system chemical drugs, musculoskeletal system chemical drugs, digestive system and metabolic chemical drugs, accounting for 6, 4 and 3 seats respectively, while Chinese patent medicines for musculoskeletal system diseases, cardiovascular and cerebrovascular diseases and respiratory system chemical drugs account for 2 each.
Among the 25 drugs to be introduced, injections are the main force, with 11 products shortlisted, followed by capsules (5) and tablets (3), of which 14 are exclusive varieties, accounting for more than half of the total. From the enterprise level, the number of products to be included in the procurement catalog such as Kelun Pharmaceutical and Shenwei Pharmaceutical is 2 or more.
List of varieties to be admitted to the hospital
Note: Band * is an exclusive variety
Source: The official website of the Sixth People's Hospital of Deyang City, compiled by Minenet
As a leading infusion solution in China, Kelun Pharmaceutical has 3 types of injections to be newly promoted, including sodium chloride injection, glucose injection and zoledronic acid injection, all of which are varieties of the national medical insurance catalog.
According to data from Minenet, the sales scale of the above three varieties in the first half of 2023 will exceed 10 billion yuan, 3.5 billion yuan, and 300 million yuan respectively in the terminals of China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as China's public medical institutions), and Kelun Pharmaceutical (according to group statistics) leads the market with a share of about 27%, 33%, and 26% respectively.
Kelun Pharmaceutical's market share of three injections in China's public medical institutions
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
Shenwei Pharmaceutical Co., Ltd. is a comprehensive enterprise group with the new Chinese medicine industry as its main business, and this time there are two varieties of new promotion institutes, namely Qihuang Tongbi soft capsule and lipid-lowering Tongluo soft capsule, both of which are the company's exclusive Chinese patent medicines.
Among them, Qihuang Tongluo soft capsule is mainly composed of Astragalus membranaceus, Cistanche, cooked rhubarb, cassia seed, etc., which has the effect of nourishing qi and nourishing blood, moistening the intestines and laxative, and is used for those with "constipation" in functional constipation syndrome differentiation, while the main ingredient of Lipid-lowering Tongluo Soft Capsule is turmeric extract, which is mainly used for blood circulation and qi, lipid reduction and turbidity, and is used for hyperlipidemia with blood stasis and qi stagnation syndrome, with chest tightness, swelling pain, precordial tingling, weak pulse, etc. In recent years, the above-mentioned two proprietary Chinese medicines have maintained double-digit or above sales growth rates in the terminals of China's public medical institutions, and the market potential is promising.
The sales growth rate of Shenwei Pharmaceutical's two proprietary Chinese medicines in China's public medical institutions
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
In addition, the list of new drugs to be admitted to the hospital also includes Ketoprofen Gel Patch from Hunan Jiudian Pharmaceutical, Huzhen Qingfeng Capsule from Yili Pharmaceutical, Shenge Bukidney Capsule from Huachun Biological Pharmaceutical, Kepra Hydrochloride Tablets from Jiangsu Kefeiping Pharmaceutical, Procaterol Hydrochloride Inhalation Solution from Nanjing Huagai Pharmaceutical, etc., covering multiple treatment categories such as musculoskeletal system, nervous system diseases, digestive system and metabolic drugs, respiratory system drugs, etc., to meet the clinical drug needs of different patients.
Source: Minenet database, official website of Deyang Sixth People's Hospital
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics, and the above sales are calculated based on the average retail price of products at the terminal. The statistics are as of April 25, if there is any omission, please correct!